AustraliaHealth

Entropy Neurodynamics (ASX:ENP) strengthened its "gut-brain" portfolio with a new US patent filing for treatment-resistant IBS.

Nova Eye Medical (ASX:EYE) upgraded FY26 sales guidance to US$22–23 million following record-breaking monthly sales in the USA.

Sigma Healthcare (ASX:SIG), via Chemist Warrehouse, secured a majority stake in the London-based Greenlight Healthcare chain.

Medical technology innovator ImpediMed (ASX:IPD) announced a $15.2 million capital raise.

Mayne Pharma (ASX:MYX) recorded a rise in commercial momentum for the third quarter of FY26.

Aged care giant Regis Healthcare (ASX:REG) has appointed Andrew Kinkade as its next CEO.

Medical Developments International (ASX:MVP) reported a 19% year-on-year revenue surge, reaching $10.5 million.

Cambium Bio (ASX:CMB) announced that the US Food and Drug Administration confirmed a streamlined approval pathway for its flagship candidate, Elate Ocular.

Nyrada (ASX:NYR) announced the activation of its first clinical trial site for the PROTECT-MI Phase 2a study.

Australian Health Minister Mark Butler is set to announce the removal of out-of-pocket costs for essential aged-care services.

Invion (ASX:IVX) announced the expansion of its clinical trial for INV043, moving into the final stage of its current non-melanoma skin cancer study.

Recce Pharmaceuticals (ASX:RCE) achieves a regulatory milestone as Indonesia's BPOM clears its Phase 3 clinical trial site for diabetic foot infection treatment.